FierceBiotech  Sep 1  Comment 
GenVec: We’re not a victim of Novartis R&D cuts badams Thu, 09/01/2016 - 07:34
FierceBiotech  Aug 26  Comment 
GenVec, encamped in penny-stock territory, risks Nasdaq delisting badams Fri, 08/26/2016 - 04:54
Reuters  Aug 5  Comment 
* For 2016, GenVec continues to anticipate a cash burn between $6.0 million and $6.5 million Source text for Eikon: Further company coverage:
SeekingAlpha  Aug 5  Comment 
newratings.com  Jul 26  Comment 
WASHINGTON (dpa-AFX) - AbbVie's (ABBV) once-daily formulation of VIEKIRA PAK to treat genotype 1 chronic hepatitis C virus infection has won FDA approval. Initially approved in December 2014, VIEKIRA PAK has all along been taken twice daily...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki